

# High Blood Pressure Rates Rise in Children, Teens

BY JEFF EVANS  
Senior Writer

The prevalence of high blood pressure among children and adolescents rose during the late 1980s and into the early 2000s despite a downward trend that prevailed during much of the prior 30 years, according to the results of national surveys conducted during 1963-2002.

From 1988 to 2002, the prevalence of high

blood pressure (HBP) in children and adolescents aged 8-17 years increased from 2.7% to 3.7%. During the same period, the prevalence of pre-HBP increased from 7.7% to 10% and rose significantly among blacks and Mexican Americans, Dr. Rebecca Din-Dzietham and her associates at Morehouse School of Medicine, Atlanta, reported.

"It is advisable to measure blood pressure at every visit with the appropriate technique to rank the child's measured blood pressure from the Centers for Dis-

ease Control and Prevention growth charts and the gender-, age-, and height-specific blood pressure table" the researchers advised (*Circulation* 2007;116:1392-1400).

They analyzed data on individuals aged 8-17 years from the second and third National Health Examination Surveys (1963-1965 and 1966-1970, respectively), the Hispanic Health and Nutrition Examination Survey (1982-1984), and the first, second, third, and continuous National Health and Nutrition Examination Surveys (1971-1975,

1976-1980, 1988-1994, and 1999-2002).

The overall trend of systolic and diastolic BP in the surveys paralleled the rise in HBP, although the mean increase in age-adjusted BP was greater for diastolic (8.4 mm Hg) than systolic BP (1.3 mm Hg). The increase in systolic BP was comparable among lean, at-risk-for-overweight, and overweight children and adolescents, but lean individuals had a significantly greater mean increase in diastolic BP than did their heavier counterparts. ■

Continued from previous page

To boost the number of patients with PAH who start treatment early, Dr. Galie suggested screening for PAH in groups that are known to have a relatively high prevalence of PAH. This includes patients with connective tissue diseases, such as scleroderma, patients infected with HIV, and patients with congenital heart disease.

Three other reports at the meeting dealt with using bosentan to treat PAH; all three studies also were sponsored by Actelion.

One study enrolled 157 patients who had a specific, relatively common form of PAH, chronic thromboembolic pulmonary hypertension (CTEPH), which was inoperable or recurrent. The results showed that treatment with bosentan was safe and led to improvements in pulmonary vascular resistance and other measures, Dr. Irene Lang, professor of vascular biology at the Medical University of Vienna, reported at the meeting.

The Bosentan Effects in Inoperable Forms of CTEPH (BENEFIT) study randomized patients to treatment with 62.5 mg bosentan b.i.d for 4 weeks, followed by 125 mg b.i.d. for 12 weeks or placebo. Their average age was 63 years. Bosentan was linked with a significant, 24% reduction in peripheral vascular resistance in 66 evaluable patients, compared with 71 placebo patients. Treatment also significantly boosted cardiac index, and cut NT-proBNP levels and dyspnea scores. Bosentan treatment had no significant effect on 6-minute walk distance.

Another study assessed the acute hemodynamic effect of a single, 25-mg dose of sildenafil in 44 patients with PAH already on chronic bosentan treatment. The results showed that the single sildenafil dose was safe, and after 60 minutes led to a significant drop in pulmonary vascular resistance, total pulmonary resistance, pulmonary artery pressure, and cardiac output.

The fourth study examined the pharmacokinetics of a new formulation of bosentan designed for use in children. Results from 35 patients aged 2-11 years showed that the formulation led to reasonable serum levels and a good safety profile.

"New drugs such as bosentan have dramatically improved outcomes for patients with pulmonary arterial hypertension. It is gratifying to see extension of the research into patients with early disease and in children," commented Dr. Daniel Jones, professor of medicine and dean of the medical school at the University of Mississippi, Jackson, and president of the American Heart Association. ■

## CALLING ALL ADOLESCENTS AND ADULTS



**A CALL TO ARMS**  
AGAINST PERTUSSIS

Pertussis protection for both adolescents and adults 11 through 64 years of age

**Adacel**<sup>®</sup>  
Tetanus Toxoid, Reduced  
Diphtheria Toxoid and Acellular  
Pertussis Vaccine Adsorbed  
Arming More People Against Pertussis



### Safety Information

ADACEL vaccine is indicated for active booster immunization for the prevention of tetanus, diphtheria, and pertussis as a single dose in persons 11 through 64 years of age.

As with any vaccine, ADACEL vaccine may not protect 100% of vaccinated individuals. There are risks associated with all vaccines. The most common injection site adverse events include pain, erythema, and swelling. The most common systemic adverse events include headache, body ache, tiredness, and fever. ADACEL vaccine is contraindicated in persons with known systemic hypersensitivity to any component of the vaccine or a life-threatening reaction after previous administration of the vaccine or a vaccine containing the same substances. Because of uncertainty as to which component of the vaccine may be responsible, no further vaccination with the diphtheria, tetanus, or pertussis components found in ADACEL vaccine should be carried out. Because any intramuscular injection can cause injection site hematoma, ADACEL vaccine should not be given to persons with any bleeding disorder, such as hemophilia or thrombocytopenia, or to persons on anticoagulant therapy unless the potential benefits clearly outweigh the risk of administration. If the decision is made to administer ADACEL vaccine to such persons, it should be given with caution, with steps taken to avoid the risk of hematoma formation following injection.

Before administering ADACEL vaccine, please see brief summary of full Prescribing Information on following page.

ADACEL vaccine is manufactured by Sanofi Pasteur Limited and distributed by Sanofi Pasteur Inc.

To order ADACEL vaccine, log onto [www.vaccineshoppe.com](http://www.vaccineshoppe.com) or call 1-800-VACCINE (1-800-822-2463)

Learn about pertussis disease and prevention at [www.ADACELVACCINE.com](http://www.ADACELVACCINE.com)

### References:

1. Centers for Disease Control and Prevention (CDC). Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. *MMWR*. 2006;55(RR-17):21-22. 2. CDC. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines: recommendations of the ACIP. *MMWR*. 2006;55(RR-3):22.

\* Advisory Committee on Immunization Practices. † Tetanus, diphtheria, and acellular pertussis. ‡ 19-64 years of age. § 11-18 years of age.

sanofi pasteur. Discovery Drive, Swiftwater, Pennsylvania 18370. [www.sanofipasteur.us](http://www.sanofipasteur.us)  
MKT12997 © 2007 Sanofi Pasteur Inc. 2/07 Printed in USA

**sanofi pasteur**  
The vaccines business of sanofi-aventis Group